Aug 2026· Human Gene Therapy· Vol 37, pp. 1056 - 1067· 0 citations· 30 references
Medicine
TL;DR
The findings indicate sustained gene transfer and transduction for at least 180 days following a single AAV1 administration to the primate lung, with minimal immunopathology, which supports the potential feasibility of extended dosing intervals and informs the development of repeatable AAV-based gene therapies for CF.
Abstract
Adeno-associated virus (AAV)–mediated gene transfer remains a promising strategy for cystic fibrosis (CF), but durability of expression and optimal dosing intervals are unresolved challenges. Here, we evaluated long-term gene transfer, transduction, and immunological responses following a single pulmonary administration of an AAV1 vector encoding Δ27–264 CFTR to juvenile rhesus macaques. Four animals received 1 × 101³ vector genomes via endotracheal spray. Two were untreated. All were analyzed 180 days post-delivery. Vector genomes were detected throughout the conducting airways and distal lung at levels ranging from ∼5 × 106 to 9 × 107 vg/µg genomic DNA. Vector genomes were also detected in extrapulmonary tissues, including liver, pancreas, spleen, heart, and kidney. Cystic fibrosis transmembrane conductance regulator (CFTR) messenger RNA expression was detected in all tissues examined and in several respiratory and extrapulmonary tissues, accompanied by increased CFTR protein expression in multiple tissues. Transgene expression was observed in airway basal cells and FOXI1-positive ionocytes, indicating targeting of key epithelial and progenitor cell populations. Despite persistence of vector genomes, immune activation was limited. Cytokine and chemokine expression profiles showed only sporadic, tissue-specific changes without evidence of coordinated inflammation. Neutralizing antibodies to AAV1 developed in all animals but did not correlate with capsid-specific T cell responses, which remained low and infrequent. These findings indicate sustained gene transfer and transduction for at least 180 days following a single AAV1 administration to the primate lung, with minimal immunopathology. The durability of expression supports the potential feasibility of extended dosing intervals and informs the development of repeatable AAV-based gene therapies for CF.
Recombinant adeno-associated viruses (rAAV) provide prolonged therapeutic protein expression in multiple target organs after single administration, delivering significant clinical benefits with a well-characterized safety profile, and can be further supported by active immune management strategies. Systemic rAAV gene t...
A novel approach to detarget liver transduction is developed by transiently downregulating the expression of key entry factors in this tissue using GalNac-siRNAs prior to AAV9 administration, which blunted hepatic transduction but also redirected the vector to other transduction-permissive tissues.
K. Kubek-Luck, J. Velazquez, Xiao-Rui Yao et al.· Molecular Therapy· 0 citations
Hepatotoxicity remains one of the most frequent and clinically important safety concerns in adeno-associated virus (AAV) gene therapy. Yet the laboratory patterns observed after vector administration are biologically complex and often difficult to interpret. Alanine aminotransferase (ALT) and aspartate aminotransferase...
B. Henry, B. Bénichou, M. Y. Rincon et al.· Clinical Biochemistry· 0 citations
Chronic kidney disease (CKD) is associated with progressive renal dysfunction, Klotho deficiency, and activation of profibrotic signaling. This study evaluated the functional and molecular effects of kidney-directed adeno-associated virus serotype 9 (AAV9)-mediated human Klotho delivery in experimental CKD. Forty-eight...
The results showed the potential of a combinatorial AAV library for model validation and revealed the human microliver platform-PEG as a reliable system for the development of AAV therapeutics.
Carmen Unzu, Amanda X. Chen, Liliana Mancio-Silva et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.